Biomerica announces inFoods IBS product featured in Biotherapeutics Quarterly

Biomerica (BMRA) announced that its inFoods IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue of Biotherapeutics Quarterly. The article, titled “Precision Medicine for IBS: A Novel, IBS-Specific Immune Response Guided Dietary Therapy”, presents comprehensive clinical and scientific insights into the company’s innovative approach to managing Irritable Bowel Syndrome. The publication details results from a randomized, multicenter, double-blind, placebo-controlled clinical trial evaluating the effectiveness of the inFoods IBS test in identifying patient-specific dietary IBS triggers and guiding targeted food elimination to reduce IBS symptoms. The inFoods IBS clinical trial analyzed 223 IBS patients across eight major U.S. academic medical centers including Mayo Clinic, Harvard Beth Israel Deaconess Medical Center, and Cleveland Clinic. Participants were tested for abnormal antibody responses to 18 IBS-specific foods using the inFoods IBS assay and then randomized into two study arms: Treatment Group: Eliminated foods identified by the inFoods IBS test as producing an abnormally elevated IgG immune response. Control Group: Followed a placebo diet eliminating foods for which the patient tested negative in the inFoods IBS test, matched in type and quantity to ensure blinding. Key Findings: 59.6% of patients in the inFoods IBS-guided diet achieved the FDA-defined target for abdominal pain reduction, compared to 42.1% in the control group for all IBS subclasses. Particularly strong results were observed in difficult-to-treat IBS subtypes: IBS-C: 67.1% response vs. 35.8% in controls; IBS-M: 66.0% response vs. 29.5% in controls. These findings demonstrate that patients following the inFoods IBS-guided elimination diet experienced a significantly greater symptom relief than those following the placebo diet. Unlike prior studies that were often limited by small sample sizes, non-IBS-specific assays, single-center designs, or inadequate control diets, the inFoods IBS study was specifically designed to overcome these limitations using an IBS-specific food panel and robust statistical methodology. The inFoods IBS assay employs a proprietary discriminatory p-value method that identifies foods producing abnormal IgG responses unique to IBS patients, minimizing unnecessary dietary restrictions and focusing only on foods with statistical and clinical relevance. Compared to broad dietary strategies such as the low-FODMAP diet – commonly described as restrictive, difficult to follow long-term, and costly – the inFoods IBS protocol typically results in the elimination of only 2 to 4 foods per IBS patient on average, offering a more practical and sustainable option for patients. The study’s strong outcomes, particularly in IBS-M patients – a subgroup for which no FDA-approved medications currently exist – underscore the potential of a diagnostic-guided dietary strategy to address an important unmet clinical need. The findings support the evolving shift toward precision medicine in gastrointestinal care, where individualized biological markers guide tailored treatment decisions rather than generalized dietary or pharmaceutical approaches.